Clinical trial

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

NCT05063136

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Capecitabine+endocrine therapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo+endocrine therapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-09-28

PhasePHASE3

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

Capecitabine+endocrine therapyDRUG

Placebo+endocrine therapyDRUG

Sponsors & collaborators

Henan Cancer Hospitallead sponsor

Mapped research locations

ZhengzhouHenan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05063136 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.